07:00 , Apr 28, 2016 |  BC Innovations  |  Finance

Virtually biotechs

Harvard University 's $20 million licensing deal with Merck & Co. Inc in March for a preclinical cancer therapy brought in more cash in one swoop than the university's tech transfer office saw in all...
01:11 , Mar 22, 2016 |  BC Extra  |  Company News

Merck licenses small molecules from Harvard

Merck & Co. Inc. (NYSE:MRK) is paying Harvard University $20 million up front in exchange for an exclusive, worldwide license to preclinical small molecule inhibitors of enzymes that regulate transcription to treat acute myelogenous leukemia...
08:00 , Nov 12, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Tool compounds for probing cyclin dependent kinase 8 (CDK8)- and cyclin dependent kinase 19 (CDK19; CDC2L6)-dependent tumor growth

CDK8 CDK19 cyclin dependent kinase 8 cyclin dependent kinase 19 CDC2L6 Cardiff University Merck Serono S.A. Merck KGaA The Institute of Cancer Research...
07:00 , Aug 23, 2012 |  BC Innovations  |  Targets & Mechanisms

CDK8 inhibitor: Senex's best thing

Chemotherapy is used to treat virtually every tumor type, but the drugs can blunt their own efficacy by inducing paracrine activity. Now, an international team led by Senex Biotechnology Inc. has mouse data showing that...
07:00 , Aug 16, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Cyclin dependent kinase 8 (CDK8); CDK19 (CDC2L6); cyclin-dependent kinase inhibitor 1A (p21, Cip1; CDKN1A; CIP1) In vitro and mouse studies suggest dual CDK8 and...